Evidence map›Paper›PMID 35149697›Full record

ArticleCell death discovery2022

Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p.

Wei Lv, Yunlong Jia, Jiali Wang, Yuqing Duan, Xuexiao Wang, Tianxu Liu, Shuwei Hao, Lihua Liu

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. BIN1 in cancer: biomarker and therapeutic target.Journal of cancer research and clinical oncology · 2023
    Review
  15. The Role of EMT-Related lncRNAs in Ovarian Cancer.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei LvDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Yunlong JiaDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Jiali WangDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Yuqing DuanDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Xuexiao WangDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Tianxu LiuDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Shuwei HaoDepartment of Gynecology, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China.
Lihua LiuDepartment of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University and Hebei Cancer Institute, 050035, Shijiazhuang, China. cdlihualiu@aliyun.com.ORCID http://orcid.org/0000-0002-1201-4624
Hebei Medical University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81871894National Natural Science Foundation of China (National Science Foundation of China) 91942314
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is one of the most frequent and fatal gynecologic malignant tumors resulting in an unsatisfying prognosis. Long non-coding RNAs (lncRNAs) play pivotal roles in the tumorigenesis and progression of EOC. However, the profile of lncRNAs involved in EOC remains to be expanded to further improve clinical treatment strategy. In present study, we identified a novel tumor-suppressive lncRNA small nucleolar RNA host gene 10 (SNHG10) in EOC. Kaplan-Meier analysis and COX proportional hazard progression model showed that low expression of SNHG10 was correlated with a poor prognosis of EOC patients. Overexpressing SNHG10 suppressed the proliferation, colony formation, migration, and invasion of EOC cells. Furthermore, SNHG10 was predicted to sponge miR-200a-3p in EOC cells according to the LncBase v.2 experimental module. Then, the binding of SNHG10 and miR-200a-3p was confirmed by performing quantitative real-time PCR (qRT-PCR) and luciferase reporter assays. RNA immunoprecipitation (RIP) showed that SNHG10 and miR-200a-3p occupied the same Ago2 protein to form an RNA-induced silencing complex (RISC). By overlapping the results from the bioinformatics algorithms, tumor-suppressor bridging integrator-1 (BIN1) was found to be a main downstream target of the SNHG10/miR-200a-3p axis. Low expression of BIN1 in EOC tissues was detected by using immunohistochemistry (IHC). Besides, BIN1 and SNHG10 expression was positively correlated in EOC tissues. By performing miRNA rescue experiments, a SNHG10/miR-200a-3p/BIN1 axis and its promoting effects on malignant behaviors and epithelial-mesenchymal transition (EMT) process were verified in EOC cells. Moreover, SNHG10 overexpression significantly suppressed the tumorigenesis and EMT of EOC cells in vivo. Altogether, SNHG10 sponges miR-200a-3p to upregulate BIN1 and thereby exerting its tumor-suppressive effects in EOC. Therefore, the SNHG10/miR-200a-3p/BIN1 axis may act as a potential predictive biomarker and therapeutic target for treating EOC.

Identifiers

PMID35149697
PMCPMC8837780
OpenAlexW4211019209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.